世界の樹状細胞がんワクチン免疫療法市場(~2026):投与量・価格・臨床試験インサイト

◆英語タイトル:Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price and Clinical Trials Insight 2026
◆商品コード:KUIK21FB008
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年10月
◆ページ数:230
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Multi UserUSD5,100 ⇒換算¥581,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界の樹状細胞がんワクチン免疫療法市場について調査・分析を行い、イントロダクション、免疫系&癌治療における樹状細胞の関連性、作用機序、併用療法、研究&技術協力、市場動向、地域別動向、臨床試験状況、投与量・有効性・価格分析、その他の前立腺癌治療薬との比較評価、臨床パイプライン、将来見通し、競争状況などを掲載しています。
・イントロダクション
・免疫系&癌治療における樹状細胞の関連性
・作用機序
・併用療法
・研究&技術協力
・市場動向
・地域別動向
・臨床試験状況
・投与量・有効性・価格分析
・その他の前立腺癌治療薬との比較評価
・臨床パイプライン
・将来見通し
・競争状況
【レポートの概要】

“Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price and Clinical Trials Insight 2026″ Report Highlights:

Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook
Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication and Phase
Dosage, Efficacy and Price Insight of Provenge , Apceden and CreaVax

In the past few years, significant breakthroughs in the medical research have led to the opening of novel doors to harness the immune system of the body against the cancer cells. For the very first time in the history of cancer therapeutics , researchers have discovered a cure that incorporates dendritic cells. The introduction of dendritic cell vaccine immunotherapy into the cancer therapeutics has caused several scientific and medical hurdles to overcome as the opportunities linked with dendritic cells treatment for the cancer patients are huge.

Dendritic cell vaccine immunotherapy among all the immunotherapy treatments is considered as the most potent antigen presenting cells for the proliferation of the T-cells. The uniqueness embedded in the treatment have prompted their applications to be involved in majority of the treatments as well as wider-acceptance across the globe. The potential of immune system in fighting cancer cells got recognized three-four decades before. Since then, technological and innovative advancement in scientific knowledge have led to the development of novel ally for the cancer patients, which has now become the only hope for declining the cancer mortality rate.

The opening of novel research frontiers with the understanding of biological mechanisms underlying the human cancer and immune system are estimated to be creating promising trends and opportunities for the researchers, patients, physicians and the stakeholders. In addition, some of the factors that are leading to the exponential growth of the market in terms of revenue and size are increasing cancer cases, awareness about the advantages of the dendritic cell vaccine immunotherapy, technology advancement and many more. The dendritic cell vaccine immunotherapy market is catalyzed by a completely and exciting novel range of disruptive technologies required for the re-definition of cancer therapeutics market. In the next few years, researchers are estimated to bring a shift in the treatment paradigm where temporary respite of the cancer treatment will not be boosted in the cancer therapeutic challenge. In the new world, dendritic cell vaccine immunotherapy is estimated to be conquering all the challenges that were challenging to conquer before the arrival of the therapy.

The dendritic cell vaccine immunotherapy market for the cancer patients is estimated to be driven by major three developments advancement in the technology, groundbreaking mechanism of action of the dendritic cells against the cancer cells and consumerization of health through increased access to the patient data provided by artificial intelligence. Unlike, chemotherapy or radiation therapy with which disadvantages are more than advantages, dendritic cell vaccine immunotherapy is estimated to be bursting that bubble. The clinical successes achieved through the therapy has led to the downfall of the hype generated by the old and traditional therapies and eventually boosted the products that are already in the market for the consumption.

The future of the market is estimated to reveal the durability of the clinical responses as well as there will be a significant improvement with respect to broad spectrum development of the market. The downward pressure on the pricing of the developed drugs is estimated to change the upsetting of the market, leading to a great emphasis on the market expansion and acceptance at an international level. Along with these, the market is also observing major players emerging for the overall development of the market.

As per the analysis for Dendritic cell vaccine immunotherapy market, it is estimated that the arrival of the therapy into the market has ended the long-waiting scenario of a therapy capable of efficiently manipulating the dendritic cells and targeting it against the cancer cells. The global healthcare industry for cancer was in an urgent need of such promising therapy where patients could have increased five-year survival rate, minimum side-effects, better targeting ability of the manipulated cells and many more. The unprecedented market drivers are providing a deep insight of the market with respect to the overall progression and its aim to re-define the overall success meter in cancer market as the therapy is tending to perform with high rate of performance.

【レポートの目次】

Introduction to Dendritic Cell Cancer Vaccine
1.1 Dendritic Cell Cancer Vaccine Historical Development

1.2 Dendritic Cell Vaccines: A New Era for Cancer Immunotherapy

Relevance of Dendritic Cells in Immune System and Cancer Therapy
2.1 Dendritic Cell: Integral Part of Human Immune System

2.2 Effects of Cancer on Dendritic Cell Mediated Immunity

Dendritic Cell Cancer Vaccines: Mechanism of Action
3.1 Manufacturing of Dendritic Cell Vaccines

3.2 Mechanism of Dendritic Cell Vaccine against Cancer Cells

Dendritic Cell Cancer Vaccine In Combination Therapy
4.1 Radiotherapy

4.2 Monoclonal Antibodies

Research and Technological Collaborations for Advancing the Dendritic Cell Immunotherapy Market
5.1 UCLA Researchers Re-Defying Research for Dendritic Cell Immunotherapy

5.2 Personalized Dendritic Cell Vaccine Improving the Overall Survival Rate of

Glioblastoma Patients

5.3 Cutting-Edge Grant Approval for Dendritic Cell Immunotherapy Market

Advancement in UCLA

5.4 Dendritic Cell Cytokines Leading to Increased Clinical Outcome in Case of

Different Cancer Types

5.5 Human Telomerase Reverse Transcriptase (hTERT)‐Expressing Autologous

Dendritic Cells (hTERT‐DCs) Efficiency in Case of Acute Myeloid Leukemia

5.6 APAC Biotech Company to Deliver Dendritic Cell Immunotherapy in India

5.7 Nimbus Therapeutics and Celgene to Work Together for Expanding the Applications

of Dendritic Cell Therapy

5.8 Specific Dendritic Cell Vaccines ATTAC Study Result for the Treatment of

Glioblastoma

5.9 Bristol Myers Squibb and UbiVac Announces Collaboration for Dendritic Cell-

Targeted Microvesicle (DPV-001)

5.10 Cancer Research UK and VOLT to Conduct First-in-Human Trial for Dendritic Cell

Therapy

5.11 University of California San Diego Research Work for Confirming the Efficacy of

Dendritic Cell Cancer Vaccines

5.12 Interleukin-32 Dendritic Cell Therapy Provoking Promising Strategy Treatment

5.13 Elicio Therapeutics and Moffitt to Evaluate the Combinational Outcomes for AMP-

CD19 and CD19 CAR-T Cells

5.14 Dendritic Cell Immunotherapy Discovery as Novel Guards for Immune System

5.15 Non-Small Cell Lung Cancer Treatment by Autologous Dendritic Cancer Cell

Vaccines

5.16 Dendritic Cell Immunotherapy Preliminary Reports for Solid and Haematological

Malignancies

Global Dendritic Cell Cancer Vaccine Immunotherapy Current Market Overview

Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook
7.1 North America

7.2 India

7.3 South Korea

7.4 Japan

Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Landscape
8.1 By Phase

8.2 By Patient Segment

8.3 By Company

8.4 By Country

8.5 By Cancer

Dendritic Cell Cancer Vaccine Immunotherapy – Dosage, Efficacy and Price Insight
9.1 Provenge

9.2 Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)

9.3 CreaVax RCC

Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer
10.1 Provenge v/s Jevtana

10.1.1 Clinical Efficacy

10.1.2 Treatment Course and Dosage

10.1.3 Therapy Price Analysis

10.2 Provenge v/s Zytiga

10.2.1 Clinical Efficacy

10.2.2 Treatment Course and Dosage

10.2.3 Therapy Price Analysis

Global Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication and Phase
11.1 Unknown

11.2 Research

11.3 Preclinical

11.4 Phase-0

11.5 Phase-I

11.6 Phase-I/II

11.7 Phase-II

11.8 Phase-II/III

11.9 Phase-III

Marketed Dendritic Cell Vaccines Immunotherapy Clinical Insight
12.1 CreaVax

12.2 Sipuleucel-T (Provenge)

12.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells – Shanghai Jia Fu Medical

Promising Future of Dendritic Cell Vaccines in Various Cancer
13.1 Dendritic Cell Vaccine in Stage-III Melanoma

13.2 Dendritic Cell Vaccine in Acute Myeloid Leukemia

13.3 Dendritic Cell Vaccine in Brain Tumor

Global Dendritic Cell Cancer Vaccine Market Dynamics
14.1 Favorable Market Parameters

14.2 Market Growth Challenges

Global Dendritic Cell Cancer Vaccine Market Future Outlook
15.1 Future Course for Market

15.2 Dendritic Cell Cancer Vaccine Technical Advancements

15.3 Availability of Target Patient Base for Dendritic Cell Cancer Vaccines

Competitive Landscape
16.1 3M Company

16.2 Activartis

16.3 Argos Therapeutics

16.4 Batavia Bioservices

16.5 Bellicum Pharmaceuticals

16.6 Creagene

16.7 DanDrit Biotech

16.8 DCPrime

16.9 Dendreon Corporation

16.10 Elios Therapeutics

16.11 ImmunoCellular Therapeutics

16.12 Immunicum

16.13 Kiromic

16.14 Medigene

16.15 Merck

16.16 Northwest Biotherapeutics

16.17 Glaxo Smith Kline

16.18 ImmunoCellular Therapeutics

16.19 SOTIO

16.20 Tella Incorporation

16.21 Theravectys

16.22 Vaxil BioTherapeutics



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の樹状細胞がんワクチン免疫療法市場(~2026):投与量・価格・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆